Between 60% and 78% of people with psoriasis carry overweight or obesity, and weight worsens both the disease and the response to treatment, a relationship set out in the psoriasis comorbidity evidence. A phase 3b trial at 72 US sites tested treating both at once, randomizing 274 adults to the biologic ixekizumab with or without tirzepatide [1].
The headline result is large. At week 36, 27.1% of the combination arm simultaneously reached complete skin clearance and lost at least 10% of their weight, against 5.8% on the biologic alone, a risk difference of 21.2% (95% CI 12.8%–29.7%).
The number that answers the actual question is the skin-only one. Complete clearance was 40.6% with tirzepatide against 29.0% without, a risk difference of 11.6% whose confidence interval runs from 0.3% to 22.9% (P = .04). The lower bound sits three tenths of a percent above zero. That is a positive result by convention and the most fragile figure in the trial, and it is the one a dermatologist weighing whether to add a second drug actually needs.
Two design features deserve weight here. The trial was open-label, so everyone knew who was receiving what, and PASI scoring involves investigator judgment — a combination that tends to favor the more intensively treated arm on a visually assessed endpoint. And gastrointestinal events were more frequent on the combination, which the trial reports as consistent with known safety profiles but which is still a tolerability cost attached to the extra 11.6%. The same class of stomach complaints is described from the mechanism side in nausea and appetite on one circuit.
What the trial does establish, and it is not nothing, is that the two drugs can be given together for a year without a new safety signal emerging, in a population where doing so was previously untested at this scale. Whether the skin benefit is worth a second injection is a judgment the confidence interval leaves genuinely open. The broader pattern of these drugs producing modest effects across many separate conditions runs through the heart failure evidence and the carpal tunnel comparison.